iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
0.7255
-0.0045 (-0.62%)
Jun 26, 2025, 12:17 PM - Market open
iBio, Inc. Revenue
iBio, Inc. had revenue of $375.00K in the twelve months ending March 31, 2025, up 650.00% year-over-year. In the fiscal year ending June 30, 2024, iBio, Inc. had annual revenue of $225.00K.
Revenue (ttm)
$375.00K
Revenue Growth
+650.00%
P/S Ratio
17.61
Revenue / Employee
$23,438
Employees
16
Market Cap
11.77M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
IBIO News
- 2 days ago - iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results - GlobeNewsWire
- 2 days ago - iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call - GlobeNewsWire
- 10 days ago - iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - GlobeNewsWire
- 7 weeks ago - iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - GlobeNewsWire
- 7 weeks ago - iBio Reports Fiscal Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - iBio Raises $6.2 Million Through Warrant Inducement Transaction - GlobeNewsWire
- 2 months ago - iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - GlobeNewsWire
- 2 months ago - iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - GlobeNewsWire